Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.1900 (-4.07%) ($5.1900 - $5.1900) on Mon. Jun. 21, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.71% (three month average) | RSI | 46 | Latest Price | $5.1900(-4.07%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.6% a day on average for past five trading days. | Weekly Trend | ADMS advances 0.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) ONLN(51%) XBI(29%) ARKK(27%) IPO(29%) TAN(20%) | Factors Impacting ADMS price | ADMS will decline at least -1.855% in a week (0% probabilities). BOTZ(-22%) SMH(-60%) INDA(-52%) IWF(-48%) XLE(-45%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.855% (StdDev 3.71%) | Hourly BBV | -0.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.21(-0.38%) | 10 Day Moving Average | $5.12(1.37%) | 20 Day Moving Average | $5.13(1.17%) | To recent high | -11.6% | To recent low | 3.6% | Market Cap | $147m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |